Based on the TG Therapeutics Inc stock forecast from 5 analysts, the average analyst target price for TG Therapeutics Inc is USD 42.25 over the next 12 months. TG Therapeutics Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of TG Therapeutics Inc is Slightly Bullish , which is based on 9 positive signals and 6 negative signals. At the last closing, TG Therapeutics Inc’s stock price was USD 32.16. TG Therapeutics Inc’s stock price has changed by +3.52% over the past week, -7.08% over the past month and +89.18% over the last year.
No recent analyst target price found for TG Therapeutics Inc
No recent average analyst rating found for TG Therapeutics Inc
Company Overview TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina. Read Less
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for...Read More
Frequently Asked Questions About TG Therapeutics Inc (TGTX) Stock
Based on ratings from 5 analysts TG Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TGTX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for TGTX is USD 42.25 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 20.
TGTX stock's Price/Earning ratio is 34.35.
Our analysis grades TGTX stock's Price / Earning ratio at F. This means that TGTX stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TGTX may be a overvalued for its sector.
The last closing price of TGTX's stock was USD 32.16.
The most recent market capitalization for TGTX is USD 5.01B.
Based on targets from 5 analysts, the average taret price for TGTX is projected at USD 42.25 over the next 12 months.
This means that TGTX's stock price may go up by +31.37% over the next 12 months.
We can't find any ETFs which contains TG Therapeutics Inc's stock.
As per our most recent records TG Therapeutics Inc has 319 Employees.
TG Therapeutics Inc's registered address is 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560.
You can get more information about it from TG Therapeutics Inc's website at https://www.tgtherapeutics.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Revenue Growth
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About TG Therapeutics Inc (TGTX) Stock
Based on ratings from 5 analysts TG Therapeutics Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 7 buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on TGTX's stock to indicate if its a good dividend stock.
Based on targets from 5 analysts, the average taret price for TGTX is USD 42.25 over the next 12 months. The maximum analyst target price is USD 55 while the minimum anlayst target price is USD 20.
TGTX stock's Price/Earning ratio is 34.35.
Our analysis grades TGTX stock's Price / Earning ratio at F. This means that TGTX stock's Price/Earning ratio is above 80% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this TGTX may be a overvalued for its sector.
The last closing price of TGTX's stock was USD 32.16.
The most recent market capitalization for TGTX is USD 5.01B.
Based on targets from 5 analysts, the average taret price for TGTX is projected at USD 42.25 over the next 12 months.
This means that TGTX's stock price may go up by +31.37% over the next 12 months.
We can't find any ETFs which contains TG Therapeutics Inc's stock.
As per our most recent records TG Therapeutics Inc has 319 Employees.
TG Therapeutics Inc's registered address is 3020 Carrington Mill Blvd., Morrisville, NC, United States, 27560.
You can get more information about it from TG Therapeutics Inc's website at https://www.tgtherapeutics.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for TGTX !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
